๐Ÿ”ฌDeep Research

INVA โ€” Innoviva Inc ยท catalysts, narrative & risks

ยท21 sourcesINVA forecast โ†’

Company Profile

Across the new sources, Innoviva is consistently described as a "diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets" [1], [2], [4], [8]. Its legacy royalty stream is tied to GSK respiratory products (Relvar/Breo Ellipta, Anoro Ellipta, Trelegy Ellipta) marketed for asthma and COPD [19].

Key Recent Catalysts (last ~1โ€“3 months)


AI-assisted research from the K3vl4r desk โ€” not personalized investment advice. More research โ†’